Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 4/2016

Open Access 01-12-2016 | Review

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease

Authors: Bosco Paes, Brigitte Fauroux, Josep Figueras-Aloy, Louis Bont, Paul A. Checchia, Eric A. F. Simões, Paolo Manzoni, Xavier Carbonell-Estrany

Published in: Infectious Diseases and Therapy | Issue 4/2016

Login to get access

Abstract

Introduction

The REGAL (RSV evidence—a geographical archive of the literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This third publication covers the risk and burden of RSV infection in infants with chronic lung disease (CLD), formerly called bronchopulmonary dysplasia (BPD).

Methods

A systematic review was undertaken of publications between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov. Studies reporting data for hospital visits/admissions for RSV infection among infants with CLD/BPD who were not prophylaxed, as well as studies reporting RSV-associated morbidity, mortality, and healthcare costs, were included. Burdens of disease data were compared with preterm infants without CLD/BPD, other high-risk groups and term infants. Study quality and strength of evidence (SOE) were graded using recognized criteria.

Results

A total of 1837 studies were identified and 39 were included. CLD/BPD is a significant independent risk factor for RSV hospitalization [RSVH (odds ratio 2.2–7.2); high SOE]. Infants and young children with CLD/BPD had high RSVH rates which were generally similar in Europe, the United States, and Canada, mostly varying between 12 and 21%. Infants with CLD also had a longer length of hospital stay than other high-risk groups and term infants (high SOE). On average, infants spent 4–11 days in hospital (moderate SOE). Once hospitalized for RSV, affected children were at risk for a more severe course of disease than children with no RSVH (moderate SOE).

Conclusion

Severe RSV infection in infants and young children with CLD/BPD poses a significant health burden in Western countries. Further studies focussing on the burden of RSV infection in this well-recognized population at high risk for severe disease are needed to help improve outcomes and plan allocation of healthcare resources.

Funding

AbbVie.
Appendix
Available only for authorised users
Literature
1.
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55.CrossRefPubMedPubMedCentral
2.
Hilgendorff A, Reiss I, Ehrhardt H, Eickelberg O, Alvira CM. Chronic lung disease in the preterm infant. Lessons learned from animal models. Am J Respir Cell Mol Biol. 2014;50:233–45.PubMed
3.
Piedmonte G, Perez MK. Respiratory syncytial virus and bronchiolitis. Pediatr Rev. 2014;35:519.CrossRef
4.
Rietveld E, De Jonge HC, Polder JJ, Vergouwe Y, Veeze HJ, Moll HA, et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J. 2004;23:523–9.CrossRefPubMed
5.
Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, Medicines for Neonates Investigator Group, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS ONE. 2014;9:e89186.CrossRefPubMedPubMedCentral
6.
Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90:F64–8.CrossRefPubMedPubMedCentral
7.
Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865–70.CrossRefPubMed
8.
Berger TM, Aebi C, Duppenthaler A, Stocker M, Swiss Pediatric Surveillance Unit. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005). Infection. 2009;37:109–16.CrossRefPubMed
9.
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415–20.CrossRef
10.
Robinson JL, Le Saux N, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015;20:321–33.PubMedPubMedCentral
11.
Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, Italian Society of Neonatology, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97.CrossRefPubMedPubMedCentral
12.
Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la SENeo, et al. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. An Pediatr (Barc). 2015;82:199e1–2.CrossRef
13.
Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, et al. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother. 2011;17:254–63.CrossRefPubMed
14.
Chi H, Hsu CH, Chang JH, Chiu NC, Hung HY, Kao HA, et al. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan. PLoS ONE. 2014;27(9):e100981.CrossRef
15.
AlAql F, Al-Hajjar S, Bin Mahoud L, Al-Alaiyan S, Tufenkji H, Abuzaid S, et al. Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia. Int J Pedatric Adolesc Med. 2016;3:38–42.CrossRef
16.
Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3:888–900.CrossRefPubMed
17.
Bont L, Checchia P, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016 (Epub ahead of print).
18.
Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A. 2014;100:145–57.CrossRef
19.
Bancalari E. Is persistent need for supplemental oxygen a good indicator of adverse pulmonary outcome in very immature infants? Arch Dis Child Fetal Neonatal Ed. 2014;99:F254–5.CrossRefPubMed
20.
Jain D, Bancalari E. Bronchopulmonary dysplasia: clinical perspective. Birth Defects Res A. 2014;100:134–44.CrossRef
21.
Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med. 1967;276:357–68.CrossRefPubMed
22.
Maitre NL, Ballard RA, Ellenberg JH, Davis SD, Greenberg JM, Hamvas A, Prematurity and Respiratory Outcomes Program, et al. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol. 2015;35:313–21.CrossRefPubMedPubMedCentral
23.
Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Prematurity and Respiratory Outcomes Program, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc. 2015;12:1822–30.CrossRefPubMed
24.
Walsh MC, Szefler S, Davis J, Allen M, Van Marter L, Abman S, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006;117:S52–6.PubMed
25.
Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23:451–6.CrossRefPubMed
26.
27.
28.
Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank. Methods Research Report. AHRQ Publication No. 13-EHC106-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2013. www.​effectivehealthc​are.​ahrq.​gov/​reports/​final.​cfm. Accessed March 2016.
29.
Ricart S, Marcos MA, Sarda M, Anton A, Muñoz-Almagro C, Pumarola T, et al. Clinical risk factors are more relevant than respiratory viruses in predicting bronchiolitis severity. Pediatr Pulmonol. 2012;48:456–63.CrossRefPubMed
30.
Tatochenko V, Uchaikin V, Gorelov A, Gudkov K, Campbell A, Schulz G, et al. Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol. 2010;2:221–7.PubMedPubMedCentral
31.
Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162:230–6.PubMed
32.
Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999;104:894–9.CrossRefPubMed
33.
Rossi GA, Medici MC, Merolla R, Osservatorio VRS Study Group. Incidence of respiratory syncytial virus positivity in young Italian children referred to the emergency departments for lower respiratory tract infection over two consecutive epidemic seasons. Infection. 2005;33:18–24.CrossRefPubMed
34.
Simon A, Müller A, Khurana K, Engelhart S, Exner M, Schildgen O, DSM RSV Paed Study Group, et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection—results from a prospective multicenter German surveillance study. Int J Hyg Environ Health. 2008;211:241–50.CrossRefPubMed
35.
Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, Osservatorio VRS Study Group, et al. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the Osservatorio VRS Study (2000–2004). New Microbiol. 2006;29:35–43.PubMed
36.
Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J, IRIS Study Group, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J. 2000;19:592–7.CrossRefPubMed
37.
Wang EE, Law BJ, Robinson JL, Dobson S, Al Jumaah S, Stephens D, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics. 1997;99:E9.CrossRefPubMed
38.
Eriksson M, Bennet R, Rotzén-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91:593–8.CrossRefPubMed
39.
Berner R, Schwoerer F, Schumacher RF, Meder M, Forster J. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr. 2001;160:541–7.CrossRefPubMed
40.
Bonillo Perales A, Díez Delgado Rubio J, Ortega Montes A, Infante Márquez P, Jiménez Liria M, Batlles Garrido J, et al. Perinatal history and hospitalization for bronchiolitis. A comparison with the impact-RSV Study Group. An Esp Pediatr. 2000;53:527–32.CrossRefPubMed
41.
Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88:1065–9.CrossRefPubMedPubMedCentral
42.
Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis. 2001;20:452–9.PubMed
43.
Pezzotti P, Mantovani J, Benincori N, Mucchino E, Di Lallo D. Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy. BMC Pediatr. 2009;9:56.CrossRefPubMedPubMedCentral
44.
Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28:511–7.CrossRefPubMed
45.
Pérez Pérez G, Navarro Merino M, Romero Pérez MM, Sáenz Reguera C, Pons Tubío A, Polo Padillo J. Respiratory morbidity after hospital discharge in premature infants born at < or =32 weeks gestation with bronchopulmonary dysplasia. An Pediatr (Barc). 2004;60:117–24.CrossRef
46.
Broughton S, Bhat R, Roberts A, Zuckerman M, Rafferty G, Greenough A. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants. Arch Dis Child. 2006;91:26–30.CrossRefPubMed
47.
48.
The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–7.CrossRef
49.
Pedersen O, Herskind AM, Kamper J, Nielsen JP, Kristensen K. Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birthweight in Denmark. Acta Paediat. 2003;92:240–2.CrossRefPubMed
50.
Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001;85:463–8.CrossRefPubMedPubMedCentral
51.
Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants—implications for use of RSV immune globulin. Arch Dis Child. 2000;83:122–7.CrossRefPubMedPubMedCentral
52.
Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 2004;23:1081–5.PubMed
53.
Groothuis JR, Fryzek JP, Makari D, Steffey D, Martone WJ. Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998–2008. Clin Epidemiol. 2011;3:245–50.CrossRefPubMedPubMedCentral
54.
Flamant C, Hallalel F, Nolent P, Chevalier JY, Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr. 2005;164:93–8.CrossRefPubMed
55.
Simon A, Ammann RA, Wilkesmann A, Eis-Hübinger AM, Schildgen O, Weimann E, DSM RSV Paed Study Group, et al. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr. 2007;166:1273–83.CrossRefPubMed
56.
Grimaldi M, Cornet B, Milou C, Gouyon JB. Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis. Arch Pediatr. 2002;9:572–80.CrossRefPubMed
57.
Zaw W, McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost. Scott Med J. 2003;48:108–10.PubMed
58.
Duppenthaler A, Gorgievski-Hrisoho M, Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med Wkly. 2001;131:146–51.PubMed
59.
Van de Steen O, Miri F, Gunjaca M, Klepac V, Gross B, Notario G, et al. The burden of severe respiratory syncytial virus disease among children younger than 1 year in Central and Eastern Europe. Infect Dis Ther. 2016 (Epub ahead of print).
60.
Arnold SR, Wang EE, Law BJ, Pediatric Investigators Collaborative Network on Infections in Canada, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J. 1999;18:866–9.CrossRefPubMed
61.
Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89:673–8.CrossRefPubMedPubMedCentral
62.
Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-Miguel A. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study. Medicine (Baltimore). 2015;94:e831.CrossRef
63.
Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212–9.CrossRefPubMed
64.
Navas L, Wang E, de Carvalho V, Robinson J, Pediatric Investigators Collaborative Network on Infections in Canada. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr. 1992;121:348–54.CrossRefPubMed
65.
Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116:1353–60.CrossRefPubMed
66.
McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014;11(Suppl 3):S146–53.CrossRefPubMedPubMedCentral
Metadata
Title
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease
Authors
Bosco Paes
Brigitte Fauroux
Josep Figueras-Aloy
Louis Bont
Paul A. Checchia
Eric A. F. Simões
Paolo Manzoni
Xavier Carbonell-Estrany
Publication date
01-12-2016
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 4/2016
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-016-0137-7

Other articles of this Issue 4/2016

Infectious Diseases and Therapy 4/2016 Go to the issue

Original Research

Cross-Sectional Survey of Perceived Barriers Among Community Pharmacists Who Do Not Immunize, in Wayne County, Michigan

Original Research

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates

Review

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review

Original Research

Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis

Review

Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How

Review

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits